Endothelial dysfunction: Potential clinical implications

Minerva Medica

Volumn 101, Issue 4, 2010, Pages 271-283

  Tousoulis, D ^a   Koutsogiannis, M ^a   Papageorgiou, N ^a   Siasos, G ^a   Antoniades, C ^a   Tsiamis, E ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiotensins; Inflammation; Thrombosis

Indexed keywords

ANTIOXIDANT; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; NITRIC OXIDE; TETRAHYDROBIOPTERIN;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOTHELIAL DYSFUNCTION; GENE CONTROL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFLAMMATION; REVIEW; RISK FACTOR; THROMBOSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; ATHEROSCLEROSIS; BIOPTERIN; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FOLIC ACID; GENE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; NITRIC OXIDE; RISK FACTORS;

EID: 79251493807     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111: 3481-3488.
2. Muller G, Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid Redox Signal 2009;11:1711-31.
3. Tousoulis D, Antoniades C, Koumallos N, Marinou K, Stefanadi E, Latsios G et al. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411-21. (Pubitemid 44941972)
4. Glasser S, Selwyn A, Ganz P. Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996;131:379-84. (Pubitemid 26043402)
5. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease:from marvel to menace. Circulation 2006;113:1708-14.
6. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976;235:825-827.
7. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ES. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002;163:193-197.
8. Varughese GI. The impact of diabetes mellitus on endothelial dysfunction. South Med J 2007;100:128-9.
9. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA):a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002;45:1609-16.
10. Vaziri ND, Rodriguez-Iturbe B.Mechanisms of disease:oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2:582-93.
11. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thrornb Vasc Biol 2000;20:2032-7.
12. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-55. (Pubitemid 23326094)
13. Holay MP, Paunikar NP, Joshi PP, Sahasrabhojney VS, Tankhiwale SR. Effect of passive smoking on endothelial function in:healthy adults. J Assoc Physicians India 2004;52:114-7.
14. Davis JW. Some acute effects of smoking on endothelial cells and platelets. Adv Exp Med Biol 1990;273:107-18.
15. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections:role of endothelial dysfunction. Circulation 2002;106:184-90.
16. Jacob HS, Visser M, Key NS, Goodman JL, Moldow CF, Vercellotti GM. Herpes virus infection of endothelium:new insights into atherosclerosis. Trans Am Clin Climatol Assoc 1992;103:95-104.
17. Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001;38:1106-15.
18. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway:Role of asymmetric dimethylarginine. Circulation 2001;104:2569-75. (Pubitemid 33104795)
19. Stühlinger MC, Oka RK, Graf EE, Schmölzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia:Role of asymmetric dimethylarginine. Circulation 2003;108:933-8.
20. Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after methionine loading. Scand J Lab Invest 2003;63:347-57. (Pubitemid 37297077)
21. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002;61:609-14.
22. Lee WH, Hwang TH, Oh GT, Kwon SU, Choi YH, Park JE. Genetic factors associated with endothelial dysfunction affect the early onset of coronary artery disease in Korean males. Vasc Med 2001;6:103-8.
23. Imamura A, Okumura K, Matsui H, Mizuno T, Ogawa Y, Imai H et al. Endothelial nitric oxide synthase and methylenetetrahydrofolate reductase gene polymorphisms are associated with endothelial dysfunction in young, healthy men. Can J Cardiol 2004;20:1229-34. (Pubitemid 39545558)
24. Li D, Mehta J.L. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 2003;10:17-21. (Pubitemid 36355979)
25. Mehta JL. Pleiotropic effects of statins:How important are they in the prevention of vascular disease? Endothelium 2003;10:3-4.
26. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359-363.
27. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005;91:27-31.
28. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
29. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82. (Pubitemid 27029946)
30. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
31. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-71.
32. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells:involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59:646-54.
33. Stefanadi E, Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Vavuranakis E et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int J Cardiol 2009;133 :266-8.
34. Schmidt-Lucke C, Fichtischerer S, Rössig L, Kämper U, Dimmeler S. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010. [Epub ahead of print]
35. Sadik H, Moore T, Vail A, Murray A, Anderson M, Andrew Blann A et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology 2010;49:990-996.
36. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis:Part I:Oxidative stress and atherogenesis. Circulation 2002;105:393-6.
37. Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002;105:627-32.
38. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.
39. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. Quinapril Ischemic Event Trial. Am J Cardiol 1999;83:43-7.
40. Burch S, Ou N. Current indications for ACE inhibitors and HOPE for the future. Am J Manag Care 2002;8:478-90.
41. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Quinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001;87:542-6.
42. Vasilieva E, Urazovskaya I, Skrypnik D, Shpektor A. Total occlusion of the infarct-related coronary artery correlates with brachial artery flow-mediated dilation in patients with ST-elevation myocardial infarction. Acute Card Care 2009;11:155-9.
43. Steinberg H.O, Chaker H, Learning R, Johnson A, Brechtel G, Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-10. (Pubitemid 126497833)
44. Pasceri V, Wu H.D, Willerson J.T, Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8.
45. Caballero A, Saouaf R, Lim S, Hamdy O, Abou-Elenin K, O'Connor C et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes:a placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80.
46. Watanabe Y, Sunayama S, Shimada K, Sawano M, Hoshi S, Iwama Y. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thrornb 2000;7:159-63.
47. Fujishima, S, Ohya Y, NakamuraYet, Onaka U, Abe I, Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. Am J Hypertens 1998;11:1134-7. (Pubitemid 28451919)
48. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 2008;159:399-406.
49. Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J 1998;19:1504-11.
50. Briasoulis A, Tousoulis D, Antoniades C, Stefanadis C. The oxidative stress menace to coronary vasculature:any place for antioxidants? Curr Pharm Des 2009;15:3078-90.
51. Tousoulis D, Antoniades C, Tountas C, Bosinakou E, Kotsopoulou M, Toutouzas P et al. Vitamin C affects thrombosis/ fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2003;26:2749-53.
52. Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis:the effects of vitamin C. Diabet Med 2004;21:552-8. (Pubitemid 38746273)
53. Micheletta F, Natoli S, Misuraca M, Sbarigia E, Diczfalusy U, Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis:reversal of altered oxidative stress status in plasma but not in plaque. Arterioscler Thrornb Vasc Biol 2004;24:136-40.
54. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
55. Tousoulis D, Antoniades C, Stefanadis C. Statins and antioxidant vitamins:should co-administration be avoided? J Am Coll Cardiol 2006;47:1237.
56. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E:the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46:166-72.
57. Antoniades C, Tousoulis D, Tentolouris C, Toutouzas P, Stefanadis C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz 2003;28:628-38.
58. The GISSI trial. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-55.
59. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals:a randomised placebo-controlled trial. Lancet 2002;360:23-33.
60. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006;11:524-33.
61. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxysubstituted catechol. Am J Respir Cell Mol Biol 1994;11:95-102.
62. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension:evidence for an involvement of protein kinase C. Kidney Int 1999;55:252-60.
63. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002;90:107-11.
64. Turgeon J, Dussault S, Haddad P, Groleau J, Ménard C, Michaud SE et al. Probucol and antioxidant vitamins rescue ischemia-induced neovascularization in mice exposed to cigarette smoke:potential role of endothelial progenitor cells. Atherosclerosis 2010;208:342-9.
65. Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease:dream or reality? Vasc Med 2002;7:203-11.
66. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003;107:926-8.
67. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels:relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002;53:515-24.
68. Tousoulis D, Bouras G, Antoniades C, Marinou K, Miliou A, Papageorgiou N et al. The activation of endothelin-1 pathway during methionine-induced homocysteinemia mediates endothelial dysfunction in hypertensive individuals. J Hypertens 2010;28:925-30.
69. Tousoulis D, Xenakis C, Tentolouris C, Davies G, Antoniades C, Crake T et al. Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart 2005;91:1319-23.
70. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR. Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8.
71. Boger RH. Asymmetric dimethylarginine (ADMA):A novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-36.
72. Lucotti P, Monti L, Setola E, La Canna G, Castiglioni A, Rossodivita A et al. Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism 2009;58:1270-6.
73. Alp NJ, Channon ICM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thrornb Vasc Biol 2004;24:413-20.
74. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols:implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003;278:22546-54.
75. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S et al. Tetrahydrobiopterin improves endothelium dependent vasodilation in chronic smokers:Evidence for a dysfunctional nitric oxide synthase. Circulation Research 2000;86:36-41.
76. Nystrom T, Nygren A, Sjoholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. 665 American Journal of Physiology Endocrinology and Metabolism 2004;287:919-25.
77. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart 2002;87:264-9.
78. Tamura Y, Naemura A, Inoue A, Ijiri Y, Seki J, Yada T et al. Impaired endothelial function may be due to decreased aortic tetrahydrobiopterin, assessed by a new flow-mediated vasodilation in vivo in hypercholesterolemic/ atherogenic mice. Blood Coagul Fibrinolysis 2009;20:699-705.
79. Verhaar MC, Wever RM, Kastelein JJ, van Loon D, Milstien S, Koomans HA et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 1999;100:335-8.
80. Schnyder G, Roffi M, Pin R Flammer Y, Lange H, Eberli FR et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600. (Pubitemid 33126838)
81. Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K,. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2001;350:2673-81.
82. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. "Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death:The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial." JAMA 2004;291:565-75.
83. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid:effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-13.
84. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. N Engl J Med 2006;354:1578-88.
85. Vermeulen EG, Stehouwe CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis:a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
86. Spijkerman, AM, Smulders YM, Kostense PJ, Henry RM, Becker A, Teerlink T et al. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine:the Hoorn Study. Arterioscler Thrornb Vasc Biol 2005;25:778-84.
87. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6. (Pubitemid 34049137)
88. Antoniades C, Shirodaria C, Leeson P, Shijie C, de Bono J, Lee J et al. 5-methyl-tetrahydrofolate rapidly improves endothelial function and superoxide production in human atherosclerosis:Effects on tetrahydrobiopterin-dependent eNOS coupling. J Am Coll Cardiol 2006;47:356.
89. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-41.
90. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-34.
91. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 2005;97:864-71.
92. Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension 2006;47:87-94. (Pubitemid 43177820)
93. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-9.
94. Imamura A, Murakami R, Takahashi R, Cheng XW, Numaguchi Y, Murohara T et al. Low folate levels may be an atherogenic factor regardless of homocysteine levels in young healthy nonsmokers. Metabolism 2010;59:728-33.
95. Friedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Inter Med 2002;136:54-71.
96. Ferber D. Gene therapy. Safer and virus-free. Science 2001;294:1638-42.
97. Makinen K, Mnninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery:A randomized, controlled, double-blinded phase II study. Mol Ther 2002;6:127-33
98. Emanueli C, Maddedu P. Angiogenesis gene therapy to rescue ischaemic tissues:Achievements and future directions. Br J Pharmacol 2001;133:951-8. (Pubitemid 32762403)
99. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
100. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001;104:753-5.